Brief: BerGenBio and Oncoinvent Announce Proposed Merger and Fully Underwritten Rights Issue to Advance Cancer Therapies
30/06/2025 21:34
June 30 (Reuters) - Bergenbio ASA BGBIO.OL: BERGENBIO AND ONCOINVENT, A RISING INNOVATOR IN RADIOPHARMACEUTICAL CANCER THERAPIES, ANNOUNCE PROPOSED MERGER AND A FULLY UNDERWRITTEN RIGHTS ISSUE Source text: ID:nPnbSkw9Da Further company coverage: BGBIO.OL ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncoinvent ASA
See all newsBrief: Oncoinvent To Raise Up To NOK 140 Million In Private Placement
Brief: Oncoinvent H1 Operating Loss NOK 69 Mln
Brief: Oncoinvent Secures New Patent Expanding Protection For Radspherin
Brief: Oncoinvent's Shares To Be Consolidated In Ratio Of 100:1
Brief: Oncoinvent To Increase Share Capital In Connection With Settlement Of Underwriting Fee